Koshinski Asset Management
CRDF icon

Koshinski Asset Management’s Cardiff Oncology CRDF Stock Holding History

Koshinski Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$2.48K – 841
2022
Q1 		$2.48K Hold
1,000
– – ﹤0.01% 1935
2021
Q4 		$6.01K Hold
1,000
– – ﹤0.01% 1762
2021
Q3 		$6.66K Buy
+1,000
New +$6.28K ﹤0.01% 1774

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Koshinski Asset Management's CRDF Position: Q2 2022 in Review

Koshinski Asset Management sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 1,000 shares — an estimated $2.48K sold.

Koshinski Asset Management first reported a position in CRDF in Q3 2021 and held it in 3 quarters. The position peaked at $6.66K in Q3 2021. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • Koshinski Asset Management reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 1,000 Cardiff Oncology shares in Q2 2022, an estimated $2.48K.
  • Koshinski Asset Management first reported a position in Cardiff Oncology in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's Cardiff Oncology position peaked at $6.66K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.